Company Profile
Lenz Therapeutics Inc Stock Price, News & Catalysts
- Ticker:
- LENZ
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.13 USD (-0.24%)
Close
Last updated: September 17, 2026
224M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, LENZ was little changed and closed at $4.13. No new same-company headline was identified in the current news window.
Company overview
Presbyopia-Focused Company
LENZ Therapeutics is an ophthalmic pharmaceutical company focused on pharmacologic treatment of presbyopia, the age-related loss of near vision.
VIZZ
VIZZ is an FDA-approved aceclidine ophthalmic solution designed to improve near vision through pupil modulation while limiting accommodative stimulation. It is the company's principal commercial product and the foundation of its presbyopia franchise.
U.S. Commercial Model
LENZ markets VIZZ through eye-care professionals and an integrated telehealth and e-pharmacy channel. Consumer outreach is intended to build awareness and convert interest into prescriptions and repeat use.
International Licensing Network
The company has licensed or distributed VIZZ across multiple ex-U.S. territories. Partners are pursuing approvals and commercialization in markets including Europe, Canada, Greater China, Australia, New Zealand, and the Middle East.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lenz Therapeutics Inc (LENZ)?
Lenz Therapeutics Inc (LENZ) most recently closed at 4.13 USD, a -0.24% move versus the previous session.
What is the market cap of Lenz Therapeutics Inc (LENZ)?
Lenz Therapeutics Inc currently has a market capitalization of 224M USD on BioPharmSignal.
What does Lenz Therapeutics Inc do?
Presbyopia-Focused Company LENZ Therapeutics is an ophthalmic pharmaceutical company focused on pharmacologic treatment of presbyopia, the age-related loss of near vision. VIZZ VIZZ is an FDA-approved aceclidine ophthalmic solution designed to improve near vision through pupil modulation while limiting accommodative stimulation. It is the company's...
On which exchange is LENZ stock listed?
Lenz Therapeutics Inc (LENZ) is associated with NASDAQ, United States, Biopharma.
What is Presbyopia-Focused?
Presbyopia-Focused Company LENZ Therapeutics is an ophthalmic pharmaceutical company focused on pharmacologic treatment of presbyopia, the age-related loss of near vision.
Which conditions is Lenz Therapeutics Inc targeting with Presbyopia-Focused?
Presbyopia-Focused Company LENZ Therapeutics is an ophthalmic pharmaceutical company focused on pharmacologic treatment of presbyopia, the age-related loss of near vision. VIZZ VIZZ is an FDA-approved aceclidine ophthalmic solution designed to improve near vision through pupil modulation while limiting accommodative stimulation. It is the company's...
What is Therapeutics?
Presbyopia-Focused Company LENZ Therapeutics is an ophthalmic pharmaceutical company focused on pharmacologic treatment of presbyopia, the age-related loss of near vision.
What is FDA-approved?
VIZZ VIZZ is an FDA-approved aceclidine ophthalmic solution designed to improve near vision through pupil modulation while limiting accommodative stimulation.